UK Companies House feature
DR REDDY'S LABORATORIES (UK) LIMITED
Cash
£1M
-0.5% vs 2024
Net assets
£52M
-7.5% vs 2024
Employees
40
+11.1% vs 2024
Profit before tax
£7M
-60.2% vs 2024
Profile
- Company number
- 01729064
- Status
- Active
- Incorporation
- 1983-06-03
- Last accounts made up
- 2025-03-31
- Account category
- FULL
- Primary SIC
- 21200
- Hubs
- UK Healthcare
Net assets
7-year trend · vs UK Healthcare median
Accounts
7-year trend · latest 2025-03-31
| Metric | Trend | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | — | £40,293,293 | — | £60,797,188 | £67,366,999 | |
| Operating profit | — | — | — | £1,769,207 | — | £15,414,563 | £5,382,174 | |
| Profit before tax | — | — | — | £2,066,563 | — | £17,758,151 | £7,072,034 | |
| Net profit | — | — | — | £1,910,224 | — | £13,315,584 | £5,803,745 | |
| Cash | — | — | — | £559,225 | — | £1,363,850 | £1,357,415 | |
| Total assets less current liabilities | — | — | — | £37,068,151 | — | £56,197,200 | £52,002,608 | |
| Net assets | — | — | — | £37,055,934 | — | £56,182,542 | £51,986,287 | |
| Equity | £29,386,394 | £32,855,867 | £35,145,710 | £37,055,934 | £42,866,958 | £56,182,542 | £51,986,287 | |
| Average employees | — | — | — | 45 | — | 36 | 40 | |
| Wages | — | — | — | £3,330,328 | — | £2,577,158 | £4,526,069 |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102 §1A
- Reporting scope
- Standalone (parent only)
- Abridged
- Yes — abridged accounts (limited disclosure)
- Auditor
- Sadofskys
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”
Significant events
- “We have successfully started distribution of our first entry into the biosimilars market.”
- “Other income for the year ended 31st March 2024 included £9,550,000 which related to settlement of a product related litigation by the company and its affiliates in the United Kingdom.”
- “principal decisions taken by the Board as those decisions in 2024/25 that are of a strategic nature and that are significant to any of our key stakeholder groups. As outlined in the FRC Guidance on the Strategic Report, we include decisions related to capital allocation and dividend policy.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
7 active · 29 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| BAHETI, Anup Kumar | Secretary | 2022-05-17 | — | — |
| AGHANIAN, Patrick | Director | 2020-03-04 | Jan 1965 | Iranian |
| KUMAR, Manoj | Director | 2025-04-30 | Aug 1985 | Indian |
| MANNAM, Venkata Narsimham | Director | 2010-05-03 | May 1968 | Indian |
| OBERTE, Kristine | Director | 2024-04-30 | Aug 1978 | Latvian |
| REDDY, Kallam Satish | Director | 2005-03-14 | Jun 1967 | Indian |
| YASSAR, Mohammed | Director | 2021-05-06 | Apr 1981 | Indian |
Show 29 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BANDALI, Abbas | Secretary | 2012-07-29 | 2017-08-04 |
| BRODRICK, Andrew, Dr | Secretary | 1999-05-10 | 2002-04-11 |
| DAVIES, Robin | Secretary | 2002-04-11 | 2004-07-30 |
| NATU, Sameer | Secretary | 2004-09-27 | 2012-07-29 |
| SANE, Ramanjaneyulu | Secretary | 2017-08-04 | 2022-05-17 |
| SOLOMON, Charmian, Mrs. | Secretary | — | 1996-11-25 |
| SPURLING, Alan Malcolm | Secretary | 1996-11-25 | 1998-01-05 |
| VOERMAN, Peter | Secretary | 1998-01-05 | 1999-05-10 |
| BONTHU, Viswanatha | Director | 2002-04-11 | 2013-03-31 |
| BRODRICK, Andrew, Dr | Director | 1999-05-10 | 2002-04-11 |
| CHAPLIN, David Andrew | Director | 2018-02-20 | 2019-01-31 |
| DAVIES, Robin | Director | 1999-05-10 | 2004-07-30 |
| DE RIJCKE, Pieter Willem Jacobus | Director | 1996-11-25 | 1999-05-10 |
| EWERS, Michael | Director | 2012-05-10 | 2014-11-27 |
| GREGORY, Neil Windsor | Director | 1999-05-10 | 2005-03-14 |
| HARTMAN, Mark | Director | 2002-04-11 | 2008-10-29 |
| HAZELEBACH, Gerard Willem | Director | 1998-07-01 | 1999-05-10 |
| KILHAM, Jonathan Paul | Director | 2010-05-03 | 2013-03-31 |
| KOHLI, Subir | Director | 2013-04-10 | 2019-11-29 |
| MCAULIFFE, Sean | Director | 2020-01-01 | 2021-05-31 |
| OTTEN, Edwin | Director | 1997-05-01 | 1998-05-07 |
| REID, Cameron | Director | 2002-04-11 | 2004-04-05 |
| SAWHNEY, Arun | Director | 2004-04-13 | 2008-04-29 |
| SHEPPARD, Alan | Director | 2004-11-01 | 2007-03-31 |
| SOLOMON, Montague Cecil, Dr | Director | — | 1996-11-25 |
| TROCHE, Clemens Johannes | Director | 2014-11-27 | 2019-05-15 |
| VAN HEDEL, Theodorus Johannes Maria | Director | 1998-05-07 | 1999-05-10 |
| VASUDEVAN, Vishar Subramanian | Director | 2002-05-10 | 2010-03-30 |
| VOERMAN, Peter | Director | 1998-01-05 | 1999-05-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dr Reddys Laboratories (Eu) Ltd | Corporate entity | Shares 75–100% | 2016-04-07 | Active |
Filing timeline
Last 20 of 186 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2025-05-07 | AP01 | officers | appoint person director company with name date |
| 2025-05-06 | AA | accounts | accounts with accounts type full |
| 2025-05-06 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-05-03 | AA | accounts | accounts with accounts type full |
| 2024-05-02 | AP01 | officers | appoint person director company with name date |
| 2024-05-01 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-05-30 | AA | accounts | accounts with accounts type full |
| 2023-05-02 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-09-15 | AA | accounts | accounts with accounts type full |
| 2022-09-06 | AD01 | address | change registered office address company with date old address new address |
| 2022-06-17 | AD01 | address | change registered office address company with date old address new address |
| 2022-05-19 | TM02 | officers | termination secretary company with name termination date |
| 2022-05-19 | AP03 | officers | appoint person secretary company with name date |
| 2022-05-04 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2022-05-04 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2022-05-03 | CH01 | officers | change person director company with change date |
| 2021-12-22 | AA | accounts | accounts with accounts type full |
| 2021-06-20 | TM01 | officers | termination director company with name termination date |
| 2021-05-17 | AP01 | officers | appoint person director company with name date |
| 2021-04-30 | CS01 | confirmation-statement | confirmation statement with no updates |
Credit score
Altman Z″ (private-firm) · reference 2025-03-31
8.03
SAFE
Altman Z″
- Working capital / Total assets 0.719 × 6.56 = +4.72
- Retained earnings / Total assets 0.000 × 3.26 = +0.00
- EBIT / Total assets 0.075 × 6.72 = +0.51
- Book equity / Total liabilities 2.674 × 1.05 = +2.81
Bands: > 2.6 safe · 1.1–2.6 grey · < 1.1 distress. Z″ is a public-formula baseline, not a substitute for adverse-data signals (CCJs, charges, gazette notices) — those land in a later pass.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory